KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Current Deferred Revenue (2016 - 2026)

Sarepta Therapeutics has reported Current Deferred Revenue over the past 16 years, most recently at $443.4 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 240.4% year-over-year to $443.4 million; the TTM value through Dec 2025 reached $443.4 million, up 240.4%, while the annual FY2025 figure was $443.4 million, 240.4% up from the prior year.
  • Current Deferred Revenue for Q4 2025 was $443.4 million at Sarepta Therapeutics, down from $485.4 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $485.4 million in Q3 2025 and troughed at $22.5 million in Q3 2023.
  • A 5-year average of $138.0 million and a median of $89.2 million in 2021 define the central range for Current Deferred Revenue.
  • Biggest five-year swings in Current Deferred Revenue: tumbled 74.79% in 2023 and later skyrocketed 464.6% in 2024.
  • Year by year, Current Deferred Revenue stood at $89.2 million in 2021, then changed by 0.0% to $89.2 million in 2022, then crashed by 43.51% to $50.4 million in 2023, then surged by 158.36% to $130.3 million in 2024, then surged by 240.4% to $443.4 million in 2025.
  • Business Quant data shows Current Deferred Revenue for SRPT at $443.4 million in Q4 2025, $485.4 million in Q3 2025, and $395.4 million in Q2 2025.